Our development pipeline

DEVELOPMENT pipeline

Oncology

SOLID TUMORS

HEMATOLOGICAL MALIGNANCIES

Compound / MOA

Project

Therapeutic area

Phase

Ivosidenib + 7+3 (chimio)

S95031

Hematological malignancies (new indication)

DPC

1

2

3

Territory

Worldwide

Ivosidenib

S95031

Hematological malignancies (new indication)

DPC

1

2

3

Territory

Worldwide

Calaspargase pegol combo

S95015

Hematological malignancies (new indication)

DPC

1

2

3

Territory

Worldwide

Cemacabtagene ansegedleucel (Cema-Cel)
Anti-CD19 Allogeneic CAR-T*

S95023*

Diffuse Large B-Cell Lymphoma

DPC

1

2

3

Territory

Licensed from Cellectis and Sub-Licensed to Allogene*

ND

S227928

Hematological malignancies

DPC

1

2

3

Territory

Worldwide

Partner

Neuroscience

Compound / MOA

Project

Therapeutic area

Phase

LRRK2 inhibitor

S221237

Parkinson’s Disease

DPC

1

2

3

Territory

Worldwide

Partner

ND

S230815

Neurodevelopmental disorder

DPC

1

2

3

Territory

Worldwide

Immuno-inflammation

PCD= Preclinical development phase, 1 = Phase 1, 2 = Phase 2, 3 = Phase 3, ND= Not disclosed
*Cema-Cel (ALLO501.A /S 95023) utilize TALEN® gene-editing technology owned by Cellectis. Servier, which has an exclusive license to the anti-CD19 investigational products from Cellectis, has granted Allogene exclusive rights to develop and commercialize Cema-Cel in the U.S., all EU Member States and the United Kingdom. For other candidate products (UCART19v1 and ALLO 501) sub-licensed to Allogene,  the ongoing activities are limited to follow up of patients from discontinued trials as per regulatory obligations.